This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth | The Motley Fool This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

#AXGN #4477cf47-c5ac-4b2f-992a-4d50b43ad1f7 #coveragefilings

Origin | Interest | Match

HighMark Wealth Management Buys 158,855 Shares of Axogen Stock | The Motley Fool This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.

#AXGN #IVV #EFV #IWM #IJR #VOO #8afe2db9-629e-4bdd-ad04-e436d9049fd6 #coveragefilings #Health #Care

Origin | Interest | Match

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock Axogen (Nasdaq: AXGN) priced an upsized underwritten public offering of 4,000,000 common shares at $31.00 per share, generating gross proceeds of about $124 million (assuming no exercise of the option). The underwriters have a 30-day option to buy up to 600,000 additional shares at the public offering price less discounts and commissions. The offering is expected to close on January 23, 2026, subject to customary conditions.Axogen intends to use net proceeds to pay off and terminate its term loan facility with Oberland Capital, and for working capital, capital expenditures and other general corporate purposes. Wells Fargo Securities and Mizuho lead the deal; Canaccord Genuity and Raymond James are co-managers.

#AXGN Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

www.stocktitan.net/news/AXGN/axogen-announc...

Axogen Announces Proposed Public Offering of Common Stock Axogen (Nasdaq: AXGN) announced a proposed underwritten public offering of $85.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $12.75 million of shares. All shares will be sold by Axogen and the offering is subject to market and other conditions with no assurance of completion or final terms. Wells Fargo Securities and Mizuho are lead book-runners; Canaccord Genuity and Raymond James are co-managers. Axogen intends to use net proceeds for early payoff and termination of its Oberland Capital term loan facility, working capital, capital expenditures and general corporate purposes. The offering is being made under an automatic Form S-3ASR registration statement that became effective on January 21, 2026.

#AXGN Axogen Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/AXGN/axogen-announc...

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 Axogen (NASDAQ: AXGN) reported preliminary unaudited results for Q4 and full-year 2025. Q4 revenue is expected to be approximately $59.9 million (+21.3% vs Q4 2024) and full-year revenue is expected to be approximately $225.2 million (+20.2% vs FY 2024). Gross margin is expected to be above 74%, despite approximately $1.9 million of one-time costs tied to the FDA BLA approval of Avance® (67% of those costs are non-cash stock-compensation vesting).Cash, cash equivalents, restricted cash, and investments are expected to total about $45.5 million as of December 31, 2025, an increase of approximately $6.0 million year-over-year. The company received FDA BLA approval for Avance® on December 3, 2025. Final audited results are expected in late February 2026.

#AXGN Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

www.stocktitan.net/news/AXGN/axogen-inc-rep...

Just In: ( NASDAQ: #AXGN ) AxoGen Inc. (NASDAQ: AXGN) is a Stock Spotlight on 12/18

JUST IN: ( NASDAQ: #AXGN ) Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

NEWS: ( NASDAQ: #AXGN ) AxoGen Inc. (NASDAQ: AXGN) is a Stock Spotlight on 12/15

Trade Alerts, Monday December 8, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Mon Dec 8th - #NFGC #ELA #ZEUS #PNRG #KALU #DIBS #AXGN #SMRT #SD #HLLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

News; ( NASDAQ: #AXGN ) AXGN Price Target Alert: $39.00. Issued by H.C. Wainwright

Just In: ( NASDAQ: #AXGN ) AxoGen Inc. (NASDAQ: AXGN) Records 52-Week High Thursday Morning

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Dec 4th - #PMI #WRAP #WNW #SNCR #QCLS #PLBY #MNY #KALA #ILLR #GNPX #DXLG #BIOA #AXGN - More: crystalequityresearch.com/leading-indi... - #smallcap

Axogen (NASDAQ: AXGN) secures FDA BLA approval for Avance biologic, U.S. launch expected in Q2 2026 FDA approves Axogen’s BLA for Avance acellular nerve allograft, confirming its biologic status and supporting use across current nerve repair indications.

#AXGN Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

www.stocktitan.net/news/AXGN/axogen-announc...

BREAKING NEWS: ( NASDAQ: #AXGN ) AxoGen Inc. (NASDAQ: AXGN) is a Stock Spotlight on 11/25

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SNDK, #BKKT, #AXGN, #IONQ, #MODG

#OptionFlow #OptionsTrading #Trading

FDA Pushes Axogen's Groundbreaking Nerve Graft Review to December Following New Manufacturing Data FDA extends Axogen's Avance Nerve Graft PDUFA date to December 5, 2025 following major amendment submission. Product labeling feedback expected November 2025.

#AXGN Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

www.stocktitan.net/news/AXGN/axogen-provide...

Leading Indicators, Wednesday August 20, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Wed Aug 20th - #UPLD #TACO #SAVA #OSPN #NVNO #MCRI #LNSR #KIDS #JAMF #IRBT #RELI #ZSPC #VLN #WBH #YEXT #AXGN #BXFD #CRIS #DYAI #EXFY #FCEL #GGR #UMA #TFIN #SSTK - More: crystalequityresearch.com/leading-indi... - #smallcap

Axogen Turns Profitable as Q2 Revenue Jumps 18%, FDA Decision Looms in September Axogen posts strong Q2 with 18.3% revenue growth, turns profitable, and raises full-year guidance. Key FDA decision for nerve graft therapy expected September 2025. See details.

#AXGN Axogen, Inc. Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/AXGN/axogen-inc-rep...

Axogen, Inc. Reports 2025 First Quarter Financial Results Axogen (NASDAQ: AXGN) reported its Q1 2025 financial results, showing strong revenue growth but mixed profitability metrics. Revenue reached $48.6 million, up 17.4% year-over-year. The company's gross margin decreased to 71.9% from 78.8% in Q1 2024, impacted by increased product costs and inventory write-offs. Net loss improved to $3.8 million ($0.08 per share) compared to $6.6 million ($0.15 per share) in Q1 2024. The company maintained its 2025 guidance of 15-17% revenue growth and gross margins of 73-75%. Notable developments include the FDA's acceptance of Axogen's Biologics License Application for Avance® Nerve Graft with a decision date of September 5, 2025, and the appointment of Lindsey Hartley as new CFO effective May 12, 2025.

#AXGN Axogen, Inc. Reports 2025 First Quarter Financial Results

www.stocktitan.net/news/AXGN/axogen-inc-rep...

Axogen Announces Chief Financial Officer Transition Axogen (NASDAQ: AXGN) has announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Hartley, currently serving as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities but will remain as an advisor until July 1, 2025.Hartley brings 19 years of financial leadership experience, particularly in healthcare and medical devices. Since joining Axogen in October 2021, she has improved financial reporting processes, reduced month-end close time by 40%, and enhanced cash forecasting capabilities. Her previous experience includes roles at VERO Biotech, Brookhaven Medical, and EY.

#AXGN Axogen Announces Chief Financial Officer Transition

www.stocktitan.net/news/AXGN/axogen-announc...

Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results Axogen reported its Q4 and full-year 2024 financial results. Q4 revenue was $49.4 million, a 15.1% increase from Q4 2023. The gross margin for Q4 was 76.1%, up from 74.6% in Q4 2023. Net income for Q4 was $0.4 million ($0.01 per share), compared to a net loss of $3.9 million ($0.09 per share) in Q4 2023. Adjusted net income for Q4 was $3.5 million ($0.07 per share), versus an adjusted net loss of $2.6 million ($0.06 per share) in Q4 2023. Adjusted EBITDA for Q4 was $6.7 million, up from $0.6 million in Q4 2023. Cash and equivalents stood at $39.5 million as of December 31, 2024.For the full year, revenue was $187.3 million, a 17.8% increase from 2023. The full-year gross margin was 75.8%, slightly down from 76.6% in 2023. The net loss for the year was $10.0 million ($0.23 per share), compared to a net loss of $21.7 million ($0.51 per share) in 2023. Adjusted net income for the year was $5.9 million ($0.13 per share), versus an adjusted net loss of $7.3 million ($0.17 per share) in 2023. Adjusted EBITDA for the year was $19.8 million, compared to a loss of $1.1 million in 2023.The FDA accepted Axogen's BLA for Avance® Nerve Graft, with a PDUFA date set for September 5, 2025. Axogen will hold an Investor Day on March 4, 2025, to discuss its 2025-2028 strategic plan. The company expects 2025 revenue growth of 15%-17% and gross margins of 73%-75%.

#AXGN Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results

www.stocktitan.net/news/AXGN/axogen-inc-rep...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Feb 5th - #AXGN #BSRR #CTBI #EBTC #FLIC #GRAL #HBT #IRMD #KLTR #LEGH #NFBR #OB #PXLW #UTL #SNDA #QUAD #PINE #OOMA #NMFC #MPLN #HLQ #ECO #DOLE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Just In: ( NASDAQ: #AXGN ) Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

Axogen Reports Strong Q4: Revenue Surges 15% to $49.4M as Surgical Solutions Gain Traction Axogen delivers impressive preliminary results with 17.8% full-year revenue growth to $187.3M, driven by increased adoption of surgical solutions and strong margins above 75.5%.

#AXGN Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024

www.stocktitan.net/news/AXGN/axogen-reports...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AA, #SANA, #CEG, #PCT, #AXGN

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #AXGN ) Axogen, Inc. Announces New Leadership Appointments

#StockMarket #News